Article
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Archives of pathology & laboratory medicine - 1 Mar 2009
Zakowski Maureen F, Hussain Sanaa, Pao William, Ladanyi Marc, Ginsberg Michelle S, Heelan Robert, Miller Vincent A, Rusch Valerie W, Kris Mark G
Abstract excerpt
CONTEXT: A subset of lung adenocarcinomas appears preferentially sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR-activating mutations and never smoking are associated with response to TKIs. OBJECTIVES: To describe the morphology of adenocarcinomas responsive to TKIs, compare it to tumors in nonresponding patients, and correlate findings with EGFR mutations, gene copy...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male